Navigation Links
Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
Date:7/28/2011

WAYNE, N.J., July 28, 2011 /PRNewswire/ -- Bayer HealthCare today announced the 2011 recipients of the Bayer Hemophilia Awards Program (BHAP).  This year, the company has awarded nearly $2.5 million in funding to 18 recipients from 12 countries, including the U.S.  BHAP, the largest program of its kind for the hemophilia community, was created to help improve the understanding and treatment of hemophilia and related bleeding disorders.  The program also seeks to reduce the disease's impact on individuals and their communities, and support the next generation of care and treatment options worldwide for people with hemophilia.

BHAP supports research in bleeding disorders, ranging from studies to better understand inhibitor development and methods for treatment, gene therapy and joint care to the development of pediatric care models in underserved markets and hemophilia counseling.

"We're very pleased to award and congratulate these future hemophilia thought leaders for their exemplary passion, talent and expertise," said John E. Murphy, Ph.D., Director, Molecular Biology, Biologics Research, Bayer HealthCare. "BHAP is a reflection of Bayer's commitment to expanding the scientific and clinical knowledge that improves patient care."

The 2011 BHAP recipients were selected by a global committee of distinguished hemophilia clinicians, researchers and caregivers, and were honored at the BHAP award ceremony held in conjunction with the International Society of Thrombosis and Haemostasis (ISTH) Annual Meeting in Kyoto, Japan.  Among this year's winners are:

  • Dr. John Sheehan of the University of Wisconsin, for "Contribution of the heparin binding exosite to factor IX clearance and in vivo activity"
  • Dr. Carol Miao, Seattle Children's Research Institute, for "Immunimodulation to eradicate anti-factor VIII inhibitory antibodies"
  • Dr. Paris Margaritis, The Children's Hospital of Philadelphia, for "The role of EPCR on FVIIa-mediated hemostasis"

Since its founding in 2002, BHAP has awarded nearly 200 grants, totaling more than $22.5 million, to researchers and caregivers from 29 countries.  This support has resulted in more than 290 scientific abstracts, publications and presentations by awardees to date.

"BHAP, now in its ninth year, continues to attract high-quality applicants and awardees who are focused on advancing hemophilia treatment and patient care. Through such research, we hope to advance scientific understanding and positively affect the diagnosis and treatment of hemophilia and related bleeding disorders," said Prof. Johannes Oldenburg, chairman of the BHAP Grants, Review and Awards Committee and Head of the Institute of Experimental Haematology and Transfusion Medicine at University Clinic Bonn.  

In addition to the BHAP award ceremony at this year's ISTH Congress, Bayer is also presenting data from globally sponsored studies and country-sponsored programs.  Seventeen studies will be presented, including seven oral presentations.

About the Bayer Hemophilia Awards Program

The Bayer Hemophilia Awards Program (BHAP) supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training and other hemophilia care professionals, the program seeks to support the next generation of care and treatment options for people with hemophilia worldwide. Parties who wish to apply for the 2012 Bayer Hemophilia Awards should submit a letter of intent by November 30, 2011 to be considered. For complete information on the Program, award categories and electronic submission process, visit the Web site at bayer-hemophilia-awards.com.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia.

About Bayer HealthCare

Bayer HealthCare is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-looking statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks of Bayer.  

KN28000511


'/>"/>
SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... now offer a comprehensive in-house dental plan for all patients. Understanding that budget ... plan that gives patients a number of perks, including discounts on many valuable ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... mental health treatment has announced the opening of a new eating disorder treatment ... and intensive outpatient treatment for adults and adolescents, both males and females ages ...
(Date:11/30/2016)... Warrington, U.K. (PRWEB) , ... November 30, 2016 ... ... to address the tech functions and stylish design wanted by today’s consumers at ... , Cronovo Co-Founder Darin Philip says the new watch is “a game changer” ...
Breaking Medicine News(10 mins):